- CEO
- Xiao Li Zhou
- Full Time Employees
- 1,868
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 299, Jiayun Road Changsha HU China 410205
- IPO Date
- Dec 5, 2014
- Business
- Hunan Fangsheng Pharmaceutical Co., Ltd. Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SS) is a China-based pharmaceutical company principally engaged in the research, development, production, and sales of innovative traditional Chinese medicines and chemical drugs. The company manufactures and markets a wide range of products including garcinia cambogia tablets (藤黄健骨片), Xuesetong dispersible tablets and tablets for cardiovascular and cerebrovascular conditions, powerful loquat cream lotion, Ezhemab tablets, Xuanqi bone tablets for orthopedics, children's Jingxing cough tablets and small children's Jingxing cough granules for pediatric respiratory issues, Hesketone dispersible tablets, lysine vitamin B12 granules, cefixime tablets for anti-infection, Jinying capsules for gynecology, Pudilan anti-inflammatory tablets, Dieda Huoxue capsules for traumatology, and Xiaoqinglong capsules; these are offered in forms such as tablets, capsules, granules, oral suspensions, powders, suppositories, powder-injections, and tinctures targeting orthopedic, cardiovascular and cerebrovascular, anti-infection, pediatric, gynecological, respiratory, and other diseases. Founded in 2002 and headquartered in Changsha, Hunan province, the company operates six major production bases across China, focuses on the pharmaceutical manufacturing segment with emphasis on proprietary Chinese medicines, and integrates big health industries and medical services as a high-tech enterprise listed on the Shanghai Stock Exchange since December 5, 2014. Recent developments include its subsidiary Guangdong Fangsheng Rongke Pharmaceutical receiving clinical trial approval for a prostate cancer drug and Ziying for innovative traditional Chinese medicine in 2025, Phase 2 trial success for a stroke treatment showing superior efficacy, acquisition of licensing rights for Xiaoqinglong capsules in February 2025, extension for a blood cholesterol drug production facility, receipt of a drug registration certificate for Indobufen tablets, recognition as a 2025 National Green Factory and ranking in the top 20 Chinese traditional Chinese medicine R&D strengths in June 2025, changes in partnership shares of its merger and acquisition fund in December 2024 without impacting consolidated statements, and cancellation of a 26.65% stake acquisition in Hunan Baijun Hi-Tech Medical Investment Management Co., Ltd. in early 2025.